What's Happening?
Simulations Plus, a leader in AI-accelerated drug development, has entered into a definitive agreement to be acquired by Altaris, LLC for approximately $375 million. The acquisition will be an all-cash transaction, with Simulations Plus stockholders receiving
$18.50 per share, a 26% premium over the 60-day volume-weighted average price. The transaction is expected to close in the fourth quarter of 2026, subject to customary closing conditions and stockholder approval. Altaris plans to combine Simulations Plus with Chemical Computing Group, enhancing its capabilities in molecular design software.
Why It's Important?
This acquisition reflects the growing trend of consolidation in the healthcare and technology sectors, driven by the need for integrated, AI-driven platforms. For Simulations Plus, the deal provides immediate value to stockholders and positions the company for accelerated growth and innovation. The combination with Chemical Computing Group is expected to enhance product offerings and expand market reach, benefiting clients in the pharmaceutical and biotechnology industries. This move underscores the strategic importance of AI and software solutions in advancing drug development.
What's Next?
Following the acquisition, Simulations Plus will become a privately held subsidiary of Altaris, and its stock will no longer be traded on the Nasdaq. The company will continue to operate from its headquarters in Research Triangle Park, North Carolina. The focus will be on integrating operations with Chemical Computing Group and leveraging combined resources to drive innovation and growth in the healthcare software market.
